Pomerantz Law Firm Files Class Action Against Rocket Pharmaceuticals: Investors Urged to Join

Important Investor Alert: Class Action against Rocket Pharmaceuticals

Pomerantz LLP, a reputable law firm known for its work in corporate securities and antitrust litigation, has recently filed a class action lawsuit against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). This legal action focuses on claims that Rocket and some of its directors may have engaged in securities fraud or other illegal business practices.

As a significant update, Pomerantz is reaching out to investors who have incurred losses on their investments in Rocket Pharmaceuticals to notify them about crucial upcoming deadlines related to the lawsuit. Affected investors are encouraged to make contact with attorney Danielle Peyton via email at [email protected] or by calling 646-581-9980, toll-free at 888.4-POMLAW (Ext. 7980). It’s advisable that inquiries include essential details such as mailing addresses, contact numbers, and the quantity of shares purchased.

The lawsuit revolves around allegations of misconduct following a press release issued by Rocket on May 27, 2025. The company reported a significant update regarding its investigational gene therapy treatment, RP-A501, used for combating Danon disease. Unfortunately, the news indicated that one patient involved in the Phase 2 pivotal trial experienced a serious adverse event, leading to complications from a rare condition known as capillary leak syndrome.

This incident triggered a voluntary pause in the trial from Rocket's side, with the FDA subsequently placing a clinical hold on the study to complete a thorough evaluation. Tragically, the patient in question later passed away from an acute systemic infection, exacerbating the situation.

Following this distressing revelation, Rocket's stock took a steep dive, plummeting by $3.94 per share, equivalent to a staggering 62.84% decrease, closing at $2.33 per share on the same day of the announcement. This underlines the potential impact these events may have on investor confidence and the company's market stability.

This is where Pomerantz LLP steps in. With over 85 years of experience in fighting for the rights of the victims racked by securities fraud, Pomerantz has established a strong reputation. Founded by the esteemed Abraham L. Pomerantz, the firm has continually battled against breaches of fiduciary duty and corporate misconduct, recovering significant damages for numerous class members. The dedication of Pomerantz can be explored further by visiting their website at www.pomlaw.com.

Investors interested in participating in this class action have until August 11, 2025, to officially request to be appointed as Lead Plaintiff for the class. A copy of the complaint can be accessed on the law firm's site, providing further details on the lawsuit and any other pertinent information.

For anyone invested in Rocket Pharmaceuticals or with potential claims, it is strongly recommended to seek legal guidance and to consider the implications this lawsuit might have for their investments. In times of uncertainty, consultation with expert legal counsel can prove invaluable.

In conclusion, Pomerantz LLP is urging all investors who have suffered losses to take prompt action. This is a crucial opportunity to join a collective effort in addressing potential securities fraud and ensures that the rights of investors are defended effectively in court. Future developments in this case will likely continue to fluctuate in tandem with Rocket's stock performance and market perception. Stay informed and act wisely.